The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

Anand Singla, Mark J. Antonino, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Background: High platelet reactivity (HPR) during aspirin and clopidogrel therapy in patients with diabetes has been reported and may affect outcomes. However, the relation of platelet reactivity to glycemic control is less studied in patients on dual antiplatelet therapy. Methods: Platelet aggregation (PA) in response to 5 and 20 μmol/L adenosine diphosphate (ADP) was compared in type 2 diabetic (n = 36) and nondiabetic patients (n = 35) undergoing elective stenting on aspirin and clopidogrel maintenance therapy. The relation of glycosylated hemoglobin (HbA1c) 1c ≥7 g/dL (n = 20) on PA was examined. High platelet reactivity was defined as >46% for 5 μmol/L ADP-induced and >59% for 20 μmol/L ADP-induced PA. Results: Diabetic patients had higher 5 and 20 μmol/L ADP-induced PA than nondiabetic patients (45 ± 17 vs 33 ± 12, P = .009 and 52 ± 19 vs 40 ± 12, P = .004, respectively). Diabetic patients with HbA1c ≥7.0 g/dL had significantly higher 5 and 20 μmol/L ADP-induced PA versus patients with diabetes with HbA1c 1c ≥7 g/dL, the prevalence of HPR was 65% and 60%; and among diabetic patients with HbA1c 1c (r = 0.60 and 0.62, P = .0001, respectively). Conclusion: An important relation exists between glycemic control and platelet reactivity in patients with type 2 diabetes mellitus treated with dual antiplatelet therapy. Poorly controlled patients with diabetes have the greatest platelet reactivity and may require alternative antiplatelet strategies, and further clinical investigations are warranted.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume158
Issue number5
DOIs
StatePublished - Nov 2009

Fingerprint

clopidogrel
Aspirin
Cardiovascular Diseases
Blood Platelets
Maintenance
Platelet Aggregation
Adenosine Diphosphate
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. / Singla, Anand; Antonino, Mark J.; Bliden, Kevin P.; Tantry, Udaya S.; Gurbel, Paul A.

In: American Heart Journal, Vol. 158, No. 5, 11.2009.

Research output: Contribution to journalArticle

Singla, Anand ; Antonino, Mark J. ; Bliden, Kevin P. ; Tantry, Udaya S. ; Gurbel, Paul A. / The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. In: American Heart Journal. 2009 ; Vol. 158, No. 5.
@article{5147b200f93a4ad696f7746883f66b1f,
title = "The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy",
abstract = "Background: High platelet reactivity (HPR) during aspirin and clopidogrel therapy in patients with diabetes has been reported and may affect outcomes. However, the relation of platelet reactivity to glycemic control is less studied in patients on dual antiplatelet therapy. Methods: Platelet aggregation (PA) in response to 5 and 20 μmol/L adenosine diphosphate (ADP) was compared in type 2 diabetic (n = 36) and nondiabetic patients (n = 35) undergoing elective stenting on aspirin and clopidogrel maintenance therapy. The relation of glycosylated hemoglobin (HbA1c) 1c ≥7 g/dL (n = 20) on PA was examined. High platelet reactivity was defined as >46{\%} for 5 μmol/L ADP-induced and >59{\%} for 20 μmol/L ADP-induced PA. Results: Diabetic patients had higher 5 and 20 μmol/L ADP-induced PA than nondiabetic patients (45 ± 17 vs 33 ± 12, P = .009 and 52 ± 19 vs 40 ± 12, P = .004, respectively). Diabetic patients with HbA1c ≥7.0 g/dL had significantly higher 5 and 20 μmol/L ADP-induced PA versus patients with diabetes with HbA1c 1c ≥7 g/dL, the prevalence of HPR was 65{\%} and 60{\%}; and among diabetic patients with HbA1c 1c (r = 0.60 and 0.62, P = .0001, respectively). Conclusion: An important relation exists between glycemic control and platelet reactivity in patients with type 2 diabetes mellitus treated with dual antiplatelet therapy. Poorly controlled patients with diabetes have the greatest platelet reactivity and may require alternative antiplatelet strategies, and further clinical investigations are warranted.",
author = "Anand Singla and Antonino, {Mark J.} and Bliden, {Kevin P.} and Tantry, {Udaya S.} and Gurbel, {Paul A.}",
year = "2009",
month = "11",
doi = "10.1016/j.ahj.2009.08.013",
language = "English (US)",
volume = "158",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

AU - Singla, Anand

AU - Antonino, Mark J.

AU - Bliden, Kevin P.

AU - Tantry, Udaya S.

AU - Gurbel, Paul A.

PY - 2009/11

Y1 - 2009/11

N2 - Background: High platelet reactivity (HPR) during aspirin and clopidogrel therapy in patients with diabetes has been reported and may affect outcomes. However, the relation of platelet reactivity to glycemic control is less studied in patients on dual antiplatelet therapy. Methods: Platelet aggregation (PA) in response to 5 and 20 μmol/L adenosine diphosphate (ADP) was compared in type 2 diabetic (n = 36) and nondiabetic patients (n = 35) undergoing elective stenting on aspirin and clopidogrel maintenance therapy. The relation of glycosylated hemoglobin (HbA1c) 1c ≥7 g/dL (n = 20) on PA was examined. High platelet reactivity was defined as >46% for 5 μmol/L ADP-induced and >59% for 20 μmol/L ADP-induced PA. Results: Diabetic patients had higher 5 and 20 μmol/L ADP-induced PA than nondiabetic patients (45 ± 17 vs 33 ± 12, P = .009 and 52 ± 19 vs 40 ± 12, P = .004, respectively). Diabetic patients with HbA1c ≥7.0 g/dL had significantly higher 5 and 20 μmol/L ADP-induced PA versus patients with diabetes with HbA1c 1c ≥7 g/dL, the prevalence of HPR was 65% and 60%; and among diabetic patients with HbA1c 1c (r = 0.60 and 0.62, P = .0001, respectively). Conclusion: An important relation exists between glycemic control and platelet reactivity in patients with type 2 diabetes mellitus treated with dual antiplatelet therapy. Poorly controlled patients with diabetes have the greatest platelet reactivity and may require alternative antiplatelet strategies, and further clinical investigations are warranted.

AB - Background: High platelet reactivity (HPR) during aspirin and clopidogrel therapy in patients with diabetes has been reported and may affect outcomes. However, the relation of platelet reactivity to glycemic control is less studied in patients on dual antiplatelet therapy. Methods: Platelet aggregation (PA) in response to 5 and 20 μmol/L adenosine diphosphate (ADP) was compared in type 2 diabetic (n = 36) and nondiabetic patients (n = 35) undergoing elective stenting on aspirin and clopidogrel maintenance therapy. The relation of glycosylated hemoglobin (HbA1c) 1c ≥7 g/dL (n = 20) on PA was examined. High platelet reactivity was defined as >46% for 5 μmol/L ADP-induced and >59% for 20 μmol/L ADP-induced PA. Results: Diabetic patients had higher 5 and 20 μmol/L ADP-induced PA than nondiabetic patients (45 ± 17 vs 33 ± 12, P = .009 and 52 ± 19 vs 40 ± 12, P = .004, respectively). Diabetic patients with HbA1c ≥7.0 g/dL had significantly higher 5 and 20 μmol/L ADP-induced PA versus patients with diabetes with HbA1c 1c ≥7 g/dL, the prevalence of HPR was 65% and 60%; and among diabetic patients with HbA1c 1c (r = 0.60 and 0.62, P = .0001, respectively). Conclusion: An important relation exists between glycemic control and platelet reactivity in patients with type 2 diabetes mellitus treated with dual antiplatelet therapy. Poorly controlled patients with diabetes have the greatest platelet reactivity and may require alternative antiplatelet strategies, and further clinical investigations are warranted.

UR - http://www.scopus.com/inward/record.url?scp=70350056868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350056868&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.08.013

DO - 10.1016/j.ahj.2009.08.013

M3 - Article

C2 - 19853698

AN - SCOPUS:70350056868

VL - 158

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -